Biotech Stock Mailbag: Cardium Therapeutics
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.
01:01PM 11/13/09
Biotech Stock Mailbag: Cardium Therapeutics
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.
07:31AM 11/13/09
Biotech Stock Mailbag: Cardium Therapeutics (RealMoney.com $)
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from the phase IIb study announced on Oct. 14.
05:00AM 11/13/09
Early Movers: Pump Up the Volume
Several small-cap stocks were poised to move on above-average volume during Friday's session.
08:32AM 10/02/09
Swine Flu Daytrading (RealMoney.com $)
I expect this crisis to be over quick, but here are some ways to play it.
10:58AM 04/27/09
Here's a look back at the hits, misses and notable moments from 2008.
12:20PM 12/29/08
Biotech Mailbag: Recap on GenVec (RealMoney.com $)
Readers chime in on the its cancer drug. Also, alternative insulin delivery remains a hope.
07:45AM 11/21/08
GenVec Stock Hit by Pancreas Study's Details
GenVec's shares sank Wednesday despite what the company said was a positive update on its experimental pancreatic cancer drug TNFerad.
01:40PM 11/19/08
Friday's Winners & Losers: National City
Shares trade down 8.1% after reported regulatory action.
04:07PM 06/06/08
Health Winners & Losers: Inspire
Inspire Pharmaceuticals breaks the day's downtrend by rising on drug study results.
02:54PM 06/06/08
Feuerstein's Biotech-Stock Mailbag
The first post-ASCO mailbag includes questions on ImClone, Peregrine, GenVec, Ariad and more.
06:59AM 06/06/08
ASCO Abstract Preview: ImClone, Genentech
The American Society of Clinical Oncology, for the first time, is making research abstracts freely available to everyone ahead of the cancer drug confab. Here's a cheat sheet.
06:59AM 05/08/08
Big Money Steers Clear of Biotech
As investors shy away from risk, this week's BIO CEO confab was a bleak affair.
01:16PM 02/14/08
Feuerstein's Biotech-Stock Mailbag
Medarex's recent drop in stock price means the FDA isn't likely to approve its melanoma drug soon.
06:38PM 01/06/08



Connect with TheStreet